Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Genomma Lab Internacional SAB de CV Decides Not To Proceed With Acquisition Of Total Stake In Prestige Brands Holdings Inc
Genomma Lab Internacional SAB de announced that on May 3, 2012 it decided not to proceed with the acquisition of the total amount of the outstanding shares of Prestige Brands Holdings Inc, at a price of USD 16.60 per share due to disagreement between the parties on the offer price.
Latest Developments for Prestige Brands Holdings Inc
- Prestige Brands Holdings Inc Raises FY 2013 EPS Guidance
- Prestige Brands Holdings Inc Raises FY 2013 EPS Guidance
- Prestige Brands Holdings Inc Reaffirms FY 2013 EPS Guidance
- Genomma Lab Internacional SAB de CV Obtains Loan from Bank of America Merrill Lynch and Jefferies Finance LLC To Acquire 100% Stake in Prestige Brands Holdings Inc
Latest Key Developments in Pharmaceuticals
- USFDA Issues Warning Letter To RPG Life Sciences Ltd-Business Standard
- Alk Abello A/S Announces Positive Outcome of Pivotal Phase III Trial with Allergy Immunotherapy Tablet against House Dust Mite Allergy
- EU Fines Ranbaxy Laboratories Ltd And Others For Blocking Cheaper Drugs-Business Standard
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 Million-DJ
- Share this
- Link this
- Digg this
Follow Reuters